COST MINIMIZATION COMPARISON OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PCV13 VESUS FREE PCV10 WITH PAID CAMPAIGN

被引：0
|
作者：
Fujii, R. K. [1 ]
Mould, J. [2 ]
Roberts, C. S. [2 ]
Presa, J. [3 ]
Jardim, E. [3 ]
机构：
[1] Pfizer Inc, Sao Paulo, Brazil
[2] Pfizer, New York, NY USA
[3] Pfizer Parmaceut Inc, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A397 / A397
页数：1
相关论文
共 21 条
  • [11] COST-EFFECTIVENESS ANALYSIS OF PCV13 VS PCV10 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE IN THE VIETNAM PEDIATRIC POPULATION
    Nguyen, T.
    Cao, Thanh T.
    Phong, Nguyen L.
    Wannaadisai, W.
    Huang, L.
    VALUE IN HEALTH, 2024, 27 (12) : S74 - S74
  • [12] Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
    Perdrizet, Johnna
    Santana, Carlos Felipe S.
    Senna, Thais
    Alexandre, Rodrigo Fernandes
    de Almeida, Rodrigo Sini
    Spinardi, Julia
    Wasserman, Matt
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) : 1162 - 1172
  • [13] Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20
    Schellenberg, John J.
    Adam, Heather J.
    Baxter, Melanie R.
    Karlowsky, James A.
    Golden, Alyssa R.
    Martin, Irene
    Demczuk, Walter
    Mulvey, Michael R.
    Zhanel, George G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 : I37 - I47
  • [14] COST-EFFECTIVENESS OF REPLACING THE SEQUENCE PCV13/PPV23 WITH PCV20 IN THE FRENCH ADULT PNEUMOCOCCAL VACCINATION PROGRAM
    Fievez, S.
    Blanc, E.
    Bougeois, M.
    Sivignon, M.
    Supiot, R.
    Vietri, J.
    Perdrizet, J.
    Bellier, L.
    VALUE IN HEALTH, 2023, 26 (12) : S78 - S78
  • [15] Comparison of early effects of pneumococcal conjugate vaccines: PCV7, PCV10 and PCV13 on Streptococcus pneumoniae nasopharyngeal carriage in a population based study; The Palestinian-Israeli Collaborative Research (PICR)
    Abu Seir, Rania
    Azmi, Kifaya
    Hamdan, Ayob
    Namouz, Hanan
    Jaar, Fuad
    Jaber, Hanaa
    Rubin, Carmit
    Doron, Dafna
    Rahav, Galia
    Abdeen, Ziad
    Regev-Yochay, Gili
    PLOS ONE, 2018, 13 (11):
  • [16] A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    VALUE IN HEALTH, 2009, 12 (07) : A428 - A428
  • [17] Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
    Gomez, Jorge A.
    Pinto, Thatiana de Jesus Pereira
    Guevara, Javier Nieto
    Noronha, Tatiana Guimaraes de
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [18] HEALTH ECONOMIC IMPACT OF INFANT VACCINATION PROGRAM WITH PHID-CV AND PCV13 USING NEW EFFICACY/EFFECTIVENESS DATA. EXAMPLE OF FINLAND
    Delgleize, E.
    Torvinen, S.
    VALUE IN HEALTH, 2012, 15 (07) : A393 - A393
  • [19] Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model
    Delgleize, Emmanuelle
    Leeuwenkamp, Oscar
    Theodorou, Eleni
    de Velde, Nicolas Van
    BMJ OPEN, 2016, 6 (11):
  • [20] A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand
    Lijoy Varghese
    Louise Talbot
    Andrea Govender
    Xu-Hao Zhang
    Bruce A. Mungall
    Applied Health Economics and Health Policy, 2018, 16 : 331 - 345
123